liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
Linköping University, Department of Clinical and Experimental Medicine, Oncology. Linköping University, Department of Medical and Health Sciences, Division of Drug Research. Linköping University, Faculty of Health Sciences.
Karolinska Institute, Sweden.
Karolinska Institute, Sweden.
Linköping University, Department of Clinical and Experimental Medicine, Oncology. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Oncology.
Show others and affiliations
2013 (English)In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 24, no 8, 1994-1999 p.Article in journal (Refereed) Published
Abstract [en]

Background The oestrogen receptor (ER) co-activator amplified in breast cancer 1 (AIB1) has been suggested as a treatment predictive and prognostic marker in breast cancer. Studies have however not been unanimous.

Patients and methods AIB1 protein expression was analysed by immunohistochemistry on tissue micro-arrays with tumour samples from 910 postmenopausal women randomised to tamoxifen treatment or no adjuvant treatment. Associations between AIB1 expression, clinical outcome in the two arms and other clinicopathological variables were examined.

Results In patients with ER-positive breast cancer expressing low tumour levels of AIB1 (<75%), we found no significant difference in recurrence-free survival (RFS) or breast cancer-specific survival (BCS) between tamoxifen treated and untreated patients. In patients with high AIB1 expression (>75%), there was a significant decrease in recurrence rate (HR 0.40, 95% CI 0.26–0.61, P < 0.001) and breast cancer mortality rate (HR 0.38, 95% CI 0.21–0.69, P = 0.0015) with tamoxifen treatment. In the untreated arm, we found high expression of AIB1 to be significantly associated with lower RFS (HR 1.74, 95% CI 1.20–2.53, P = 0.0038).

Conclusion Our results suggest that high AIB1 is a predictive marker of good response to tamoxifen treatment in postmenopausal women and a prognostic marker of decreased RFS in systemically untreated patients.

Place, publisher, year, edition, pages
Oxford University Press, 2013. Vol. 24, no 8, 1994-1999 p.
Keyword [en]
AIB1, breast cancer, HER2, prognosis, SRC-3, treatment prediction
National Category
Cancer and Oncology
URN: urn:nbn:se:liu:diva-97241DOI: 10.1093/annonc/mdt159ISI: 000322339300008PubMedID: 23670096OAI: diva2:645803

Funding Agencies|Swedish Cancer Society|110504|Swedish Research Council|B0771901|

Available from: 2013-09-05 Created: 2013-09-05 Last updated: 2016-03-21

Open Access in DiVA

fulltext(237 kB)91 downloads
File information
File name FULLTEXT01.pdfFile size 237 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Weiner, MariaNordenskjöld, BoStål, Olle
By organisation
OncologyDivision of Drug ResearchFaculty of Health SciencesDepartment of Oncology
In the same journal
Annals of Oncology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 91 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 74 hits
ReferencesLink to record
Permanent link

Direct link